Debate on the Treatment of Multiple Sclerosis: Experience From an Intractable Multiple Sclerosis Case With Rebound Syndrome After Fingolimod Cessation

Clinical and Experimental Neuroimmunology - United Kingdom
doi 10.1111/cen3.12504
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Tumefactive Multiple Sclerosis Lesions Under Fingolimod Treatment

Neurology
Neurology
2012English

A Case of Posterior Reversible Encephalopathy Syndrome Associated With Gilenya® (Fingolimod) Treatment for Multiple Sclerosis

Frontiers in Neurology
Neurology
2015English

Extensive Multiple Sclerosis Reactivation After Switching From Fingolimod to Rituximab

Case Reports in Neurological Medicine
2018English

Predictors for Multiple Sclerosis Relapses After Switching From Natalizumab to Fingolimod

Multiple Sclerosis
Neurology
2014English

Comparison of Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two-Year Experience

Multiple Sclerosis Journal – Experimental, Translational and Clinical
2017English

A Case of Multiple Sclerosis With WEBINO Syndrome

Clinical Neurology
Neurology
2009English

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

Fingolimod (FTY720) as an Anti-Multiple Sclerosis Oral Ultimate Therapy

Biosciences Biotechnology Research Asia
BiotechnologyAgronomyCrop ScienceDrug Discovery
2015English

A Case of Autoimmune Myositis After Treatment With Alemtuzumab for Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy